glp-1 type 1 diabetes 🚨 Big news for people with who are using or are interested in using a GLP-1! 35 new recommendations have been published for use of GLP-1s and GLP-1/GIP in Non-insulin injectable antidiabetic drugs -

Wolf explains

That is a legitimate reason to offer it and an illegitimate reason to overstate it

The effects of L-carnitine supplementation on performance during interval swimming

Current Research on Semaglutide and Gastrointestinal Health The majority of semaglutide research has focused on weight loss and diabetes management, but secondary analyses from cardiovascular and metabolic trials reveal interesting findings about digestive health

doi:10.1016/0003-2697(73)90196-6

In addition, in a cardiovascular outcome study involving patients with type 2 diabetes, of whom more than 80% had a history of cardiovascular disease, semaglutide treatment lowered the rates of 3-point MACE (myocardial infarction, stroke and cardiovascular death) [31]